Source comparison
Melanotan-1 Dosage for EPP Treatment: Clinical Protocol Comparison
Dose per administration 16mg subcutaneous implant 0.25–1mg daily SC injection (extrapolated, not validated) Variable. No standardised EPP protocol exists Implant dosing is the only FDA/EMA-approved regimen with Phase 3 EPP efficacy data Release kinetics Zero-o
This comparison does not assign a generated winner or score.
- Dose per administration
- 16mg subcutaneous implant
- 0.25–1mg daily SC injection (extrapolated, not validated)
- Variable. No standardised EPP protocol exists
- Implant dosing is the only FDA/EMA-approved regimen with Phase 3 EPP efficacy data
- Release kinetics
- Zero-order release over 60 days
- Bolus Cmax within 30–60 min, clearance within 4–6 hours
- Dependent on formulation. Typically bolus
- Controlled release matches melanogenesis timeline; bolus dosing causes adverse events without improving photoprotection
- Plasma concentration profile
- Sustained 50–150 pg/mL for 8–10 weeks
- Peaks at 500+ pg/mL, drops below threshold within hours
- Unknown without analytical testing
- Steady-state MC1R activation requires sustained plasma levels. Daily injections create inappropriate peaks and troughs
- Adverse event frequency
- Nausea (10–15%), implant-site hyperpigmentation (8–12%)
- Nausea (40–60%), flushing, spontaneous erections (males), vomiting
- Unknown. Not studied in EPP cohorts
- Implant formulation reduces acute side effects by avoiding Cmax spikes
- Photoprotection onset
- 7–10 days post-implant
- 7–10 days (melanogenesis lag unchanged)
- Not applicable. No validated endpoint data
- Mechanism requires time regardless of delivery method. Implants sustain effect through full UV season
- Regulatory status (EPP)
- FDA-approved (Scenesse), EMA-approved
- Off-label, no clinical validation
- Research-only. Not approved for therapeutic use
- Only implant formulation has undergone EPP-specific Phase 3 trials
- The bottom line: daily subcutaneous Melanotan-1 injections are not an evidence-based EPP treatment. The 16mg implant exists because EPP photoprotection requires 60+ days of sustained melanogenesis. Not intermittent receptor stimulation.